Clinical Trial Update: Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a conditioning regimen with panobinostat, gemcitabine hydrochloride, busulfan, and melphalan before stem cell transplantation in pati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Leukemia
• Plasmacytoma

Drugs mentioned

• BUSULFAN (Busulfan)
• Gemcitabine hydrochloride (Gemcitabine hydrochloride)
• Melphalan (Melphalan)
• Panobinostat (Panobinostat)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Plasma Cell Leukemia, Plasmacytoma | Phase 2 | Status: COMPLETED | Results posted: 2025-03-18